ASX / NASDAQ Media release

9 July 2007

PHARMAXIS FILES FOR ARIDOL APPROVAL IN KOREA

- FIRST MOVE INTO ASIA -

Pharmaxis (ASX:PXS, NASDAQ:PXSL) today announced its first step into the Asian market, filing for Korean marketing approval of its lung function test Aridol.

Aridol was recently approved for marketing in 13 European countries, and is already being sold in Sweden and Australia.

Korea is the first Asian country that Pharmaxis has filed a New Drug Application, and was chosen because of the high patient numbers and acceptance of bronchial provocation tests in diagnosing and managing respiratory disease.

“Korea has an estimated 2.5 million asthma sufferers and another 185,000 new asthma cases are being diagnosed every year” said Pharmaxis Chief Executive Officer Dr Alan Robertson.

“With seven to 15 per cent of asthma patients currently referred for a bronchial challenge test and up to 160,000 tests undertaken annually, Korea represents an important base from which to launch Aridol into the Asian market. We estimate our initial target Korean market to be 80,000 patients.”

The Korean regulatory approval process is expected to complete in Q1 2008, after which Pharmaxis would seek reimbursement approval through the national health scheme. Pharmaxis plans to begin pre-marketing immediately approval is granted and is currently in discussion with potential Korean distribution partners to launch Aridol.

A simple-to-use airways inflammation test, Aridol is administered as a dry powder in a hand-held inhaler. Doctors can use the results of this test to identify airway hyper-responsiveness – a hallmark of asthma.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au.

- ends –

SOURCE: Pharmaxis Ltd, Sydney, Australia
CONTACT: David McGarvey - Chief Financial Officer
Ph: +61 2 9454 7200 or email david.mcgarvey@pharmaxis.com.au

RELEASED THROUGH:

United States:
Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com
Australia:
Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

About Aridol

Asthma is among the top 10 most commonly cited reasons for consulting a General Practitioner (GP). Yet GPs currently rely upon older tests that are often inaccurate and cumbersome to assess airway inflammation in patients with asthma. The easy to administer test uses a patented formulation of mannitol processed into a breathable powder. The test requires the patient to inhale increasing doses of Aridol, which causes the airways to narrow and contract that is simply detected by measuring the amount of air a person can exhale in one second. The smaller the dose required to cause contraction, the more severe the patient's asthma diagnosis. People without airway inflammation do not respond to an Aridol challenge test. Doctors can use the results of this test to identify airway hyper-responsiveness – a hallmark of asthma.

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and autoimmune diseases. Its development pipeline of products include Aridol™ for the management of asthma, Bronchitol™ for cystic fibrosis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.

Founded in 1998, Pharmaxis was listed on the Australian Stock Exchange in November 2003 (symbol PXS), and on NASDAQ (symbol PXSL) in August 2005. The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Jane Sugden, Investor Relations +61 2 9454 7230.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.